


RECEIVED

SEP 11 2000
Sheet 1 of 2



FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 2026-4266US1	SERIAL NO. 09/529,123
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT SCHLOM ET AL.	
		FILING DATE June 13, 2000	GROUP ART UNIT TBA 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
BO	WO 92/19266	11/12/92	WIPO	—	—	—	—
BO	WO 96/26271	8/29/96	WIPO	—	—	—	—
BO	0343946	11/29/89	EPO	—	—	—	—

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

BO	•	Tsang, K.Y., et al., Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. <i>J. Natl. Cancer Inst.</i> , 87:982-990. (1995).
BO	•	Jameson, S.C., et al., T cell receptor antagonists and partial agonists. <i>Immunity</i> , 2: 1-11, (1995).
BO	•	Chen, Y., et al., Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonist and TCR antagonism with or without partial activation. <i>J. Immunol.</i> , 157: 3783-3790. (1996).
BO	•	Tsang, K.Y., et al., J. Phenotypic Stability of a Cytotoxic T Cell Line Directed Against an Immunodominant Epitope of Human Carcinoembryonic Antigen. <i>Clinical Cancer Res.</i> , 12:2349. (1997).
BO	•	Zaremba, S. et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. <i>Cancer Research</i> , 57:4570-4577. (1997).
BO	•	Ras, E. et al. "Identification of Potential HLA-A*0201 Restricted CTL Epitopes Derived from the Epithelial Cell Adhesion Molecule and the Carcinoembryonic Antigen (CEA)" <i>Hum. Imm.</i> 53:81-89 (1997).
BO	•	Madden et al. "The Antigenic Identity of Peptide-MHC Complexes: A Comparison of the Conformation of Five Viral Peptides presented by HLA-A2" <i>Cell</i> 75:693-708 (1993).

EXAMINER <i>Am De Leon</i>	DATE CONSIDERED 5-29-02
-------------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2026-4266US1	SERIAL NO. 09/529,121
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT SCHLOM ET AL.	
				FILING DATE June 13, 2000	GROUP ART UNIT TBA 1644
		Skipper et al. "An HLA-A2-restricted Tyrosinase Antigen on Melanoma Cells from Post-translational Modification and Suggests a Novel Pathway for Processing of Membrane Protein" <i>J. Exp. Med.</i> (1996).			
EXAMINER <i>Am De Leon</i>			DATE CONSIDERED <i>5-29-02</i>		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					



M&F REV. 06/29/95